In various FGFR3-activated tumor models, the diminished antitumor effectiveness due to targeted FGFR3 therapy could be counterbalanced by combining it with anti-PD-1 immunotherapy, thus significantly reducing tumor growth. This evidence concerns the gene FGFR3 and neoplasm.